Dr. Cirrito is an assistant professor in the at Washington University Department of Neurology, St Louis and a member of the faculty at the Knight Alzheimer’s Disease Research Center. In addition, he is the director of the In Vivo Microdialysis Core of the Hope Center for Neurological Disorders, a division he opened in 2007 to screen compounds for their ability to reduce brain interstitial fluid (ISF) Aβ levels.

Dr. Cirrito’s research has focused on understanding the metabolism of Aꞵ and its accumulation as toxic oligomers and plaques within the brain ISF. He has developed in vivo microdialysis techniques that enable him to specifically measure ISF Aꞵ within the brains of awake wild-type and APP transgenic mice, providing kinetic information about how Aꞵ levels change over time under various settings such as aging, behavior, drug treatment and genetic manipulation. One aspect of his current research is focused on postsynaptic signaling mechanisms that decrease Aꞵ generation.

In 2016, Dr. Cirrito received a MetLife Promising Investigator Awards for Medical Research in Alzheimer’s Disease.

Dr. Lemere is an associate professor of neurology at Harvard Medical School and an associate neuroscientist in the Ann Romney Center for Neurologic Diseases at Brigham & Women’s Hospital. In addition, she is on the speakers bureau for the Massachusetts Alzheimer’s Disease Research Center.

Her interests include the role of the immune system in Alzheimer’s disease and therapeutic potential of immune proteins on clearance of Aꞵ from the brain; better understanding of the progression of Alzheimer’s disease in individuals with Down syndrome; and the relationship of pyroglutamate Aꞵ to Alzheimer’s disease and its value as a therapeutic target.

Dr. Lemere serves on the ADPD Scientific Advisory Council, the Brightfocus Foundation Scientific Review Council, the National Alzheimer’s Association Medical and Scientific Advisory Council and the DIAN-TU Therapeutic Evaluation Committee. She received a grant in 2014 from NASA’s Human Research Program to study the impact of space radiation on cognition, synapses and biomarkers in aging and Alzheimer’s disease.

Dr. Cahill serves as a lecturer in biochemistry and molecular cell biology at the School of Biomedical Sciences at Charles Sturt University. In 2016, he was elected to the CSU Academic Senate, the university’s highest level of academic decision making and quality assurance.

Prior to his academic appointment in Australia, Dr. Cahill spent 18 years in Germany where in 2000 he co-founded a proteomics-based biotechnology company with the goal of developing and commercializing a platform for improved protein detection. In 2001, the firm underwent a corporate merger to form ProteoSys AG, where he served on the managerial board and as chief research officer. At ProteoSys, Dr. Cahill directed the team that discovered differential PGRMC1 phosphorylation in cancer, a discovery that led to several patent applications.

Dr. Cahill returned to his native Australia to pursue the characterization of PGRMC1 in a university environment and has advanced this research during his academic tenure. At CSU, his research interests revolve around the role of the PGRMC1 protein in cell biology and cellular metabolic regulation.

In addition to his research responsibilities, Dr. Cahill is a member of the Australian Society for Biochemistry and Molecular Biology (ASBMS) and a member of the Cognition Therapeutics, Inc. scientific advisory board. He is currently a development grant commercial expert reviewer and a project grant reviewer for the National Health and Medical Research Council (NHMRC), Australia’s premier funding body for medical research.

Dr. LeVine is an associate professor at the University of Kentucky College of Medicine Department of Molecular and Cellular Biochemistry. In addition, he conducts research at the Sanders-Brown Center on Aging within the University of Kentucky Chandler Medical Center, one of the original ten NIH-funded Alzheimer’s Disease Research Centers.

Dr. LeVine is a world leader in the biochemistry of Aꞵ protein and drug discovery efforts directed against this target. His research focuses on biochemical and biophysical approaches to determine how toxic oligomeric forms of the Alzheimer’s Aꞵ peptide are generated and why they persist. Dr. LeVine’s goals include a detailed mechanistic understanding of oligomer formation, cellular mechanisms for dealing with intracellular misfolded proteins, and the pharmacological manipulation of these toxic oligomers for therapy. Prior to joining the University of Kentucky, he spent 28 years in research and drug discovery in the pharmaceutical industry holding scientific leadership positions at Burroughs-Wellcome, Glaxo, Parke-Davis and Pfizer.

In addition to his work at the University of Kentucky, Dr. LeVine sits on the National Scientific Advisory Council (NSAC) of the American Federation for Aging Research, a non-profit organization whose mission is to support and advance healthy aging through biomedical research. He has authored more than 100 research papers, reviews and book chapters, as well as four patents.

Dr. Craven is an associate professor in the University of Kentucky Department of Pharmacology and Nutritional Sciences. He also serves as vice chair of the University of Kentucky Medical Institutional Review Board and has received the Wethington Award for research from the University of Kentucky on three occasions.

His research interests are primarily in signaling pathways associated with cancer progression, and his laboratory has developed multiple inhibitors to different pathways associated with tumor growth, invasion and metastasis. Most recently, he has focused on sigma-2/PGRMC1 and its role in cellular signaling by helping to process or transport signaling proteins as they are being synthesized.

In addition to his responsibilities at the university, Dr. Craven serves as a scientist reviewer for the Department of Defense CDMRP program for clinical and experimental therapeutics. He maintains memberships in several professional societies including the American Association for Cancer Research and the American Society for Pharmacology and Experimental Therapeutics, sits on the editorial board of Biochemistry Research International and is a reviewer for numerous scientific journals.

Dr. Mach is the Britton Chance Professor of Radiology and the Director of the University of Pennsylvania Positron Emission Tomography (PET) Radiochemistry Program. His research interests include the development of radiotracers for imaging CNS receptors, oxidative stress, aggregated alpha-synuclein and mechanisms of cellular death. Dr. Mach pioneered the concept of using the sigma-2 receptor as a biomarker for imaging the proliferative status of solid tumors with PET and it was his group that reported the association of the sigma-2 receptor with the PGRMC1 protein complex.

Dr. Mach has served as president of the Radiopharmaceutical Sciences Council of the Society of Nuclear Medicine and Molecular Imaging and on the board of directors of the Society of Radiopharmaceutical Sciences. He recently received the Michael J. Welch Award from the Society of Nuclear Medicine for his outstanding contributions to the field of Radiopharmaceutical Chemistry. He is a scientific advisor to Cognition Therapeutics, Inc. and a founder of Accuronix Therapeutics, an oncology-focused biotechnology company developing small molecule drug conjugates that target the sigma-2 receptor.

Dr. Goate is a professor of neuroscience, neurology, genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai. A renowned neuropsychiatric researcher and molecular geneticist, she studies the molecular genetics of dementias and addiction in human populations. In addition to her teaching obligations, Dr. Goate is the director of the Ronald M. Loeb Center on Alzheimer’s Disease.

Dr. Goate has made several important scientific findings. While working with Dr. John Hardy at Imperial College in London, she reported the first mutation to cause familial Alzheimer’s disease. In 1992 she moved to Washington University where she identified the presenilin1 mutation in the Colombian kindreds now being studied in the Alzheimer’s Prevention Initiative clinical trials. She has since demonstrated that late onset Alzheimer’s disease families can carry presenilin mutations with reduced penetrance. In 2013, her team at Mount Sinai reported missense variants in PLD3 as a risk factor for Alzheimer’s and collaborated with Dr. Hardy in the identification of TREM2 as an Alzheimer’s risk factor. Since then, she has focused her research on the role of myeloid cells in the genetics of Alzheimer’s disease.

Dr. Goate has published more than 500 papers in major journals and has received numerous awards including the Khalid Iqbal Lifetime Achievement Award from the Alzheimer’s Association, the Potamkin Award and the MetLife Award for her research on Alzheimer’s disease. In 2012 she was named an Elected Fellow of the American Association for the Advancement of Science.

Dr. Malenka is the Nancy Friend Pritzker Professor of Psychiatry and Behavioral Sciences and director of the Nancy Pritzker Laboratory at the Stanford University School of Medicine. In addition, he is a faculty member at Bio-X, Stanford’s interdisciplinary biosciences institute, and the Wu Tsai Neurosciences Institute.

He is a world leader in the molecular mechanisms of how neurons communicate with one another and how this communication is modified during learning and by experience. Dr. Malenka’s current research aims to elucidate what molecular events are responsible for triggering the various forms of synaptic plasticity.

Beyond his obligations at Stanford, Dr. Malenka serves on the National Advisory Council on Drug Abuse. In addition, he serves on the Scientific Council of the Brain and Behavior Research Foundation, in which role he reviewed grant applications and mentored National Alliance for Research on Schizophrenia & Depression (NARSAD) grantees. He was elected to the Institute of Medicine of the National Academy of Sciences in 2011 and received the Julius Axelrod Prize in 2016 by the Society for Neuroscience.